PDEX

ANALYST NOTE: PDEX (Pro-Dex, Inc.) Date: 2026-06-13 Current Price: $64.37

1. Structural Readiness

State: Forming Aggressive/Pre-Breakout Entry: N/A (Current price is holding above support, but structure is not confirmed as a breakout) Current Price: $64.37 Extension: Not applicable (Price has not yet fired the breakout signal). ATR Context: Current ATR is 5.4% (High). This indicates elevated volatility, which is within the historical "sweet spot" (4–6%) for structural quality, suggesting the setup has sufficient momentum to move but requires careful position sizing.

2. Thesis Layer

Thesis Classification: Tactical / Setup-Led Secular Exposure: None named at this date. Analysis: As of 2026-06-13, PDEX does not carry a named macro or secular thesis (e.g., "AI in Healthcare" or "Global Aging"). It is a tactical, setup-led name. Conviction must be derived strictly from the quality of the structural setup (the forming coil) and the underlying business fundamentals (backlog, customer concentration, and recent M&A). We do not invent a thesis; we judge the setup quality and the business health.

3. Business Overview

Company Description: Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered, and electric multi-function surgical drivers and shavers. These tools serve the orthopedic, thoracic, and maxillofacial (CMF) markets. Business Model: The company operates a dual-model:

Industry: Healthcare / Medical Devices (specifically Surgical Instruments). Key Evidence (PIT as of 2026-06-13):

• Manufacturing & Sales: Selling surgical handpieces and components to Original Equipment Manufacturers (OEMs) and directly to the medical device sector.
• Services: Offering engineering consulting, placement services, quality assurance, and regulatory compliance support.
• Product Portfolio: The company supplies sophisticated tools globally to OEMs, featuring versatile, autoclavable surgical drivers and shavers (E8, E19, E20).
• Recent M&A: On February 9, 2026, the company completed the acquisition of APM, a manufacturer of precision machined components for medical, aerospace, and defense industries. This was executed to broaden the customer base and support increased demand from a contract extension with the largest customer (E9, E10, E11).
• Backlog Strength: As of June 30, 2025, the company reported a backlog of $50.4 million, a significant increase from $19.8 million at June 30, 2024. Management expects substantially all of this backlog, plus certain subsequent orders, to be delivered during fiscal 2026 (E12, E13).
• Customer Dynamics: The company's largest customer executed a supply agreement amendment in Q1 FY2021 to continue supply through calendar 2025 and a development agreement for the next-generation handpiece. Shipments of this next-generation handpiece resumed in late Q4 FY2025 after a hold was lifted (E14, E15).
• Revenue Concentration: In fiscal 2025, the top three customers accounted for 94% of sales, with the single largest customer accounting for 75% of sales. 99% of revenue was derived from medical device products and related services (E16, E17).
• Financial Guidance: Forward consensus EPS is projected at $3.94 for FY1 and $2.78 for FY2 (E23).

4. Archetype and Conviction

Archetype: Growth Leader Rationale: The name fits the "Growth Leader" archetype due to the massive expansion in backlog (from $19.8M to $50.4M in one year), the successful resumption of shipments for next-generation products, and the strategic acquisition of APM to expand manufacturing capacity and customer reach. The "adaptive torque-limiting software" is a key differentiator in the CMF and thoracic markets (E18).

Valuation & Conviction Stack:

• Thesis Strength: Low (No named secular thesis; purely tactical).
• Evidence Quality: High. The evidence base is robust, citing specific backlog figures, M&A completion dates, and customer contract details from filings dated 2025 and 2026.
• Setup Readiness: Partial. The setup is "Forming," meaning the structure is in place but the breakout has not fired. This is a positive signal but not a confirmed entry.
• Rerating Potential: High, contingent on the successful integration of APM and the delivery of the $50.4M backlog. The high customer concentration (75% from one client) is a double-edged sword; while it provides revenue visibility, it creates execution risk.

5. Invalidations, Strengtheners, and Gaps

Invalidation Triggers:

• A significant reduction in the $50.4M backlog or a delay in the delivery of fiscal 2026 orders.
• Any disruption in the relationship with the largest customer (who accounts for 75% of sales).

Strengtheners:

• Public confirmation of successful integration of APM and expansion into the aerospace/defense sectors beyond the initial sub-assembly role.
• Evidence of diversification reducing the reliance on the single largest customer.

Gaps in Evidence:

• Profitability Margins: While gross profit data from 2014 is available (E6), current 2026 gross margin data is not explicitly detailed in the provided evidence, only backlog and revenue concentration.
• Cash Flow: Current cash flow generation is not explicitly stated for 2026, though historical data from 2014 showed positive cash flow (E4).

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Backlog expanded 154% to $50.4M in one year; Acquisition of APM completed to support demand; Next-gen handpiece shipments resumed after hold lifted. Key risks: Extreme customer concentration (75% from single client); Lack of named secular thesis; High volatility (5.4% ATR) may lead to false breakouts; Integration risk of APM. Sizing hint: Position size should be conservative given the "Forming" state and high customer concentration; treat as a partial setup. Expected path: Management expects backlog delivery throughout fiscal 2026; if APM integration succeeds and backlog converts to revenue, the forming coil should resolve to a confirmed breakout. Expected horizon: 3 to 6 months for the setup to resolve (breakout or invalidation).